CD274 and cancer: A combination of the chemotherapeutic agent with the anti-PD-L1 agent should be chosen not only for its capacity to effectively kill cancer cells and inhibit their growth but also based on its predisposition to modulate the activity of immune-active cells and to preserve the activity of the administered immunotherapy [231].